Purpose of the study

The purpose of this study is to evaluate the effectiveness and safety of Regeneron’s investigational COVID-19 antibody cocktail that may treat COVID-19.

Who may participate in this study?

You may qualify for this research study if the following applies to you:

• You are at least 18 years old
• You have recently tested positive for COVID-19 (you are infected with Coronavirus)

There are other eligibility requirements. A final decision on whether this research study might be suitable for you will be made after you complete the online and phone questionnaire and speak with the study doctor at the research site. The study doctor will explain the benefits and risks of participation in this research study.

Reimbursement

Adults with confirmed COVID infection may receive reimbursement up to $2250 related to study participation while adults with confirmed COVID who are at risk of developing severe COVID-19 symptoms may receive reimbursement up to $3650. 

The level of reimbursement varies between sites and based on the study you qualify for; details will be provided by the study doctor.

Study Sponsor

This study is sponsored by Regeneron Pharmaceuticals, Inc. Regeneron is applying its 30 years of scientific and technology expertise to advance research on the COVID-19 pandemic through the company’s COVID-19 antibody cocktail trials, which began in mid-June.